Core Insights - BriaCell Therapeutics Corp. and its subsidiary BriaPro are developing a novel multivalent platform called TILsRx aimed at enhancing cancer treatment through immunotherapy [1][4] - The TILsRx platform targets multiple tumor-associated and immune pathway targets to combat immune suppression and T cell exhaustion, thereby improving T cell activation and persistence in the tumor microenvironment [2][7] - The technology is expected to provide a preferred tolerability profile due to its selective targeting of cancer cells, potentially leading to improved clinical responses across various cancer types [8] Company Overview - BriaCell is a clinical-stage biotechnology company focused on developing innovative immunotherapies to transform cancer care [5] - BriaPro, a pre-clinical stage company, aims to enhance the body's natural ability to fight cancer through the development of binding agents and proteins [6] Technology Details - The TILsRx platform includes multifunctional agents such as soluble CD80, anti-CD3, IL-21, and anti-STEAP1, with an early candidate target being B7-H3, which is overexpressed in several cancers [2][4] - The platform is designed to improve manufacturing efficiency by combining shared core components with specific elements targeting cell surface antigens, allowing for future flexibility in immunotherapy targets [4][5] Future Prospects - The company anticipates that the multivalent approach will be effective against multiple cancer types and may synergize with existing cell-based cancer vaccine programs [5][8] - BriaCell and BriaPro are committed to advancing the TILsRx platform through pre-clinical and clinical stages to realize its full potential in cancer treatment [4][8]

Tevogen Bio will receive the remaining $8 million grant, totaling $10 million, from KRHP LLC this quarter, following a positive review of its progress, particularly in Tevogen.AI.Efficient operations with operating expenses of $9.7 million for the first three quarters of 2024.The company's AI division has advanced its PredicTcell platform using expanded datasets and wet lab science to enhance predictive modeling capabilities. WARREN, N.J., March 03, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen Bio Holding ...